<DOC>
	<DOCNO>NCT00224315</DOCNO>
	<brief_summary>We aim compare augmentation clozapine ziprasidone risperidone randomize , prospective manner .</brief_summary>
	<brief_title>Clozapine-Augmentation With Ziprasidone Risperidone , Randomized , Prospective Trial</brief_title>
	<detailed_description>Partial response schizophrenic psychosis monotherapy clozapine frequent problem clinical psychiatry . Current problem treatment resistant positive and/or negative symptom , well side effect . Therefore , different strategy augmentation apply . Based successful experience case report result work group , aim compare augmentation clozapine ziprasidone risperidone randomize , prospective manner .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Treatment resistant schizophrenic schizoaffective disorder therapy clozapine , Age 18 70 , Informed consent No informed consent , Intolerance respect ziprasidone risperidone , Contraindications respect substance , Gravidity miss anticonceptive safety Substance dependance ( excluded nicotin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Schizophrenia ,</keyword>
	<keyword>schizoaffective disorder ,</keyword>
	<keyword>treatment resistancy</keyword>
	<keyword>clozapine ,</keyword>
	<keyword>ziprasidone</keyword>
	<keyword>risperidone</keyword>
	<keyword>combination</keyword>
</DOC>